Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections

ClinicalTrials.gov ID: NCT03840616

Public ClinicalTrials.gov record NCT03840616. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules vs Fluconazole and Placebo in Treatment of Acute Vulvovaginal Candidiasis in Subjects With Recurrent Vulvovaginal Candidiasis

Study identification

NCT ID
NCT03840616
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Mycovia Pharmaceuticals Inc.
Industry
Enrollment
219 participants

Conditions and interventions

Interventions

  • Oteseconazole (VT-1161) 150mg capsule Drug
  • Fluconazole 150mg capsule Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 12, 2019
Primary completion
Dec 1, 2020
Completion
Dec 1, 2020
Last update posted
Feb 3, 2022

2019 – 2020

United States locations

U.S. sites
33
U.S. states
17
U.S. cities
33
Facility City State ZIP Site status
34 Tucson Arizona 85712
39 Encino California 91436
25 Los Angeles California 90036
22 Englewood Colorado 80112
49 Boca Raton Florida 33486
14 Gainesville Florida 32607
13 Leesburg Florida 34748
33 Loxahatchee Groves Florida 33470
36 Miami Florida 33155
17 Savannah Georgia 31406
27 Idaho Falls Idaho 83404
10 Nampa Idaho 83687
62 Chicago Illinois 60643
41 Fort Wayne Indiana 46825
30 Marrero Louisiana 70072
50 Dearborn Heights Michigan 48127
29 Saginaw Michigan 48602
55 Traverse City Michigan 49686
32 Troy Michigan 48085
26 Kansas City Missouri 64111
42 New Brunswick New Jersey 08901
47 Ocean City New Jersey 07712
37 Charlotte North Carolina 28207
38 Fayetteville North Carolina 28304
15 Columbus Ohio 43213
18 Bluffton South Carolina 29910
48 Myrtle Beach South Carolina 29572
20 Bristol Tennessee 37620
21 Murfreesboro Tennessee 37130
24 Austin Texas 78705
23 Fort Worth Texas 76104
63 Katy Texas 77450
58 League City Texas 77573

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03840616, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 3, 2022 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03840616 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →